As previously reported, Relmada Therapeutics, Inc. is party to a License Agreement dated as of January 16, 2018, as amended, with Drs. Charles E. Inturrisi and Paolo Manfredi (collectively, the “Licensor”), pursuant to which the Licensor granted the Company a license to commercialize esmethadone (REL-1017) in the context of psychiatric use and certain further inventions regarding esmethadone. On December 27, 2022, the Licensor and the Company entered into an Amendment No.

2 to the License Agreement extending the duration of the “Key Man” provisions of the License Agreement, pursuant to which the Licensor may terminate the License Agreement if terminate the employment of Chief Executive Officer, Dr. Sergio Traversa, for any reason other than for specified causes determined by a majority of Board of Directors (including fraud, gross negligence, unauthorized use of confidential information, conduct including harassment or discrimination, breach of fiduciary duty or uncured material breach), or if (a) substantially modify Dr. Traversa's job responsibilities or decision-making rights in connection with the development and commercialization of esmethadone, (b) remove him from the role of Chief Executive Officer other than in connection with a permitted change-of-control transaction, (c) materially reduce his compensation or (d) assign or transfer rights under the License Agreement or the esmethadone intellectual property without Dr. Traversa's consent, in each case (termination or the events in (a) through (d)) during a specified period, which originally ended on the later of five years from the original effective date of the License Agreement or December 31, 2022. The new amendment extended this period until December 31, 2027. The License Agreement was not otherwise modified.